Join over 800 professionals that attend our science-driven webinars to stay up-to-date with the latest research in mRNA Regulation. Watch here »
mRNA LIGHTNING™ PLATFORM
DISCOVERY OF SMALL MOLECULE mRNA DRUGS AND THEIR MECHANISMS OF ACTION
HIGH SCALE
PHENOTYPIC SCREENING
TESTING THE EFFECT OF COMPOUNDS ON mRNA BIOLOGY
Post transcription through translation
MILLIONS OF
mRNA IMAGES
VISUALIZING THE
mRNA LIFE CYCLE
ANALYZED WITH MOAi TECHNOLOGY
USING AI TO ELUCIDATE
THE MECHANISM OF ACTION
Delivering multiple chemistries…
Discovering multiple MOAs…
Early de-risking of projects with multiple shots on goal
PIPELINE OF 20 PROGRAMS
BIG PHARMA PARTNERSHIPS

Anima Biotech mRNA Lightning™ Platform

We are advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to elucidate the mechanism of action of active molecules. We develop our own pipeline and partner with pharma on additional targets.

A unique approach at the intersection of mRNA biology and Artificial Intelligence

Our Pharma Partners

For partnering inquiries, please contact [email protected].

mRNA Lightning™ Platform

Discovery of small molecule mRNA drugs and their mechanisms of action with automated high scale phenotypic screening in live mRNA biology and MOAi technology that uses AI to elucidate the mechanism of action of active molecules.

- AI driven MOA elucidation
AI Image Analysis MOA recognition
Machine Learning Guided MOA assays
mRNA images
High content imaging
High scale automated screening
Plate tower
Robot
Compound library
Automated mRNA Biology phenotypic screening
Cerebio Bioinformatics algorithms that select signature tRNA pair for an mRNA of interest
TranslationLight High content screening for mRNA translation modulators
Brightny Cloud-based big data AI mRNA image analysis identifies active and selective molecules
Compass Mechanism of action and Target ID identification
Cloud Cloud-based mRNA high scale data analysis identifies active and selective mRNA biology modulators.
mRNA images 50 million mRNA images are uploaded to the cloud server for analysis
High content imaging 50 million mRNA images are uploaded to the cloud server for analysis
High scale automated screening Fully automated screen running 24/7 for 3 weeks
Plate Tower +250,000 diverse drug-like small molecules
Robot Fully automated screen running 24/7 for 3 weeks
Compound library +250,000 diverse drug-like small molecules

Discovery of mRNA biology modulators
Lightning-Gene
mRNA regulation database. Proprietary algorithms to select a tRNA signature pair.
TranslationLight
TranscriptLight
High Content
Analysis
Lightning-Compass
AI-driven mechanism of action (MoA) elucidation
Lightning-Screen
Anima's T-Light technologies
mRNA Lightning™

Anima's discovery process for mRNA biology modulators relies on our proprietary interconnected technologies.

Lightning-Gene runs to produce an in-depth analysis of the mRNA of interest and selects its signature tRNA pair that enables us to visualize mRNA translation in live biology.

Lightning-Screen integrates Anima's T-Light technologies, TranslationLight and TranscriptLight, our primary screening assays used for the discovery of mRNA biology modulators. They capture millions of images that show the effect on mRNA biology of hundreds of thousands of compounds from our library.

The images captured during screening are automatically uploaded to the cloud to run through our proprietary High Content Analysis which selects the most promising hit compounds to move forward with. All these technologies feed and interact at every step with our MOAi, the underlying technology of Lightning-Compass, Anima’s AI based mechanism of action elucidation platform. AI driven MOA elucidation starts as early as hit generation, allowing us to de-risk compounds and progress them at an unprecedented success rate.

Computational biology + AI =

MOA elucidation with AI technology


Anima's MOAi technology has the potential to revolutionize drug discovery by enabling the identification of MOAs and molecular targets of hit compounds from phenotypic screening, a longstanding challenge in the field.

AI-driven MOA elucidation applied to mRNA regulation

AI Image Analysis
Billions of mRNA images
MOA recognition
Machine Learning Guided MOA assays

mRNA Biology Modulators Pipeline

Anima wholly owned pipeline programs are in Immunology (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau - Alzheimer's disease and Pain - Nav1.7 mRNA biology modulators). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.

Indication Target
Discovery
Optimization
IND enabling
Immunology
Lung fibrosis Collagen-1 1
Multiple fibrosis 2
Multiple fibrosis 3
Undisclosed abbvie logo 4
Oncology
Solid tumors c-Myc 5
Lymphoma 6
c-Myc tumors 7
Neuroblastoma Undisclosed 8
mKRAS tumors mKRAS 9
Undisclosed abbvie logo 10
Undisclosed 11
Neuroscience
Alzheimer TAU 12
Pain Nav 1.7 13
Undisclosed 14
Undisclosed takeda logo 15
Undisclosed 16
Huntington mHTT 17
Undisclosed lilly logo 18
Undisclosed 19
Undisclosed 20
Area Indication mRNA modulation Target
Discovery
Optimization
IND enabling
Immunology Lung fibrosis Collagen-1 1
Multiple fibrosis 2
Multiple fibrosis 3
  Undisclosed abbvie logo 4
Oncology Solid tumors c-Myc 5
Lymphoma 6
c-Myc tumors 7
Neuroblastoma Undisclosed 8
mKRAS tumors mKRAS 9
  Undisclosed abbvie logo 10
  Undisclosed 11
Neuroscience Alzheimer TAU 12
Pain Nav 1.7 13
  Undisclosed 14
  Undisclosed takeda logo 15
  Undisclosed 16
Huntington mHTT 17
  Undisclosed lilly logo 18
  Undisclosed 19
  Undisclosed 20

17 Scientific Collaborations

15 Peer Reviewed Publications

Coverage

News & Events

  • BIO International Convention 2023

    When: Jun. 5th, 2023 - Jun. 8th, 2023
    Where: Boston, MA

    Anima Biotech will be attending this year’s BIO International Convention. Our chief business officer, Kevin Pong, Ph.D., is looking forward to connecting with other industry experts. Additionnaly, he will give a corporate presentation on June. 5th at 3:45 P.M. EDT highlighting our unique approach to the discovery of small molecule mRNA drugs.

    Visit the conference website >> »

  • Oxford Global Discovery Europe

    When: Jun. 6th, 2023 - Jun. 7th, 2023
    Where: Berlin, Germany

    Anima Biotech will participate in the Oxford Global Discovery Europe event as part of Identification and Validation of Novel Targets track of the Conference held in Berlin, Germany. Our head of discovery, Yoni Sheinberger, Ph.D., will give a presentation titled, “mRNA Lighting Platform | Discovery Of mRNA Biology Modulators and Their Mechanisms of Action,” on June 6th at 12:05 p.m. CST.

    Visit the conference website » »

  • Locust Walk RNA Innovation Conference

    When: May. 9th, 2023
    Where: Virtual

    Anima Biotech has been invited to give a presentation during the Locust Walk RNA innovation event as part of the RNA-Targeting SMOLs track of the Conference held virtually on May 9th. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Advancing mRNA Lightning™ for the discovery of small molecule mRNA modulators and their mechanisms of action using p

    Download Press Release »

    Visit the organization website »